Healthcare Industry News: STOP AF
News Release - December 15, 2006
CryoCath hires Chief Financial Officer
MONTREAL, Dec. 15 (HSMN NewsFeed) - CryoCath Technologies Inc., the global leader in cryotherapy products to treat cardiovascular disease, today announced that it has hired L. Derek Lindsay as Chief Financial Officer."Derek brings with him a strong operational finance background, particularly in reporting and forecasting together with long experience in business development. As well, he has a successful track record of achieving objectives through innovative thinking and an effective management style," said Henri Vienneau, Interim CEO and Chairman of the Board of Directors. "His addition to CryoCath helps to solidify our management team as we step up Arctic Front(TM)'s commercialization across Europe and advance our pivotal STOP AF trial in the U.S."
Mr. Lindsay is a seasoned financial executive with extensive international experience. He joins CryoCath from Sierra Financial Corp., a consulting company offering financial, strategic and capital markets advice, where he served as partner. Prior to this post, Mr. Lindsay served as Vice President, Finance & Administration for Aeroplan. Mr. Lindsay also brings wide experience from various senior financial roles at BCE, Bell Canada International where among his positions he served as the CFO of Comcel, one of South America's largest cellular phone companies, Imasco and Wood Gundy. Mr. Lindsay holds an MBA from the Tuck School of business at Dartmouth and a Bachelor of Arts, Economics and French, from Middlebury College.
About CryoCath
CryoCath - www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiovascular disease. With a priority focus on providing physicians with a complete solution of catheter and surgical products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.
This press release includes "forward-looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.
Source: CryoCath Technologies
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!